Skip to content

Author

C. Rücker

We have 1 of 112 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.

These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.

A. Tuettenberg, L. Ruhnke, J. Schlöder et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.